Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 16/20 | 0.80 |
| ▸ | GSK3A | P49840 | 14/20 | 0.80 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3384007 | 0.89 | GSK3B (1.00) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL6427365 | 0.82 | GSK3A (0.73) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL3382637 | 0.80 | GSK3A (1.00) | GSK3BGSK3AMGLL | |
| SCHEMBL3384854 | 0.79 | GSK3A (1.00) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL3382636 | 0.79 | GSK3A (1.00) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL3383077 | 0.79 | GSK3A (1.00) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL3384147 | 0.76 | GSK3A (1.00) | GSK3BGSK3AMGLL | |
| SCHEMBL6427982 | 0.73 | GSK3A (0.69) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL6428649 | 0.71 | GSK3A (0.53) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL12251828 | 0.70 | FAAH (0.50) | GSK3BGSK3AFAAHMGLLAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005024755-A2 | MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS OR DIABETES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2005-03-17 | — | — | WO | disclosed |